GSK Dexedrine Adds Black Box On Cardiovascular Events
This article was originally published in The Pink Sheet Daily
Executive Summary
ADHD product also adds class warnings on psychiatric events, seizures and visual disturbance.
You may also be interested in...
Novartis’ Ritalin LA Faces Patent Challenge
Patents relate to controlled-release dosing forms.
Novartis’ Ritalin LA Faces Patent Challenge
Patents relate to controlled-release dosing forms.
Shire’s New ADHD Drug Coming Into Focus
Connexyn (guanfacine extended release) could be approved in mid-2007 and would be the second non-stimulant in category.